Mechanism of Abeta Sequestration

Abeta 封存机制

基本信息

批准号：
7569351
负责人：
RAYMOND SCOTT TURNER
金额：
$ 28.06万
依托单位：
GEORGETOWN UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-02-01 至 2012-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7569351
关键词：
Active Immunization Acute Address Adverse effects Affect Affinity Aftercare Alzheimer disease prevention Alzheimer&apos s Disease Alzheimer&apos s disease model Amino Acid Sequence Amyloid Amyloid beta-Protein Amyloidosis Animal Tarsus Antibodies Antibody Affinity Autologous Binding Binding Sites Biological Assay Biological Markers Biological Process Blood Blood - brain barrier anatomy Brain Brain region Cavia Cerebral Ventricles Clinical Clinical Trials Cognition Collection Complex Consult Data Dementia Deposition Detection Detergents Development Disease District of Columbia Dose Early Diagnosis Encephalitis Enoxaparin Environment Enzyme-Linked Immunosorbent Assay Equilibrium Extracellular Space Failure Fc Receptor Feasibility Studies Figs - dietary Functional disorder Future Gel Gelsolin Gene Expression Generations Genes Glycosaminoglycans Half-Life Heparin Hour Human Immune Immune response Immunization Immunoglobulin G Immunoglobulins Immunohistochemistry Impaired cognition Inflammatory Infusion procedures Injection of therapeutic agent International Intervention Intravenous infusion procedures Investigation Kidney Kinetics Knockout Mice Laboratories Length Letters Liver Long-Term Effects Long-Term Potentiation Low-Molecular-Weight Heparin Mass Spectrum Analysis Measurable Measures Mediating Membrane Memory Metabolism Methodology Methods Microdialysis Microglia Molecular Molecular Weight Monitor Mus Mutation Nerve Degeneration Neuraxis New York Organ Outcome Passive Immunization Pathological Staging Pathology Pathway interactions Patients Penetration Peptides Peripheral Permeability Phagocytosis Pharmaceutical Preparations Physiological Plasma Plasma Proteins Polysaccharides Prealbumin Prevention Prions Property Proteins Radioactivity Radiolabeled Rattus Reaction Reducing Agents Reporting Research Research Proposals Running Senile Plaques Site Source Specificity Specimen Spleen Staging Synthetic Genes System Techniques Testing Therapeutic Therapeutic Agents Time Transgenes Transgenic Mice Transgenic Model Transgenic Organisms Translating Universities Urine Vaccine Therapy Vaccines Western Blotting Withdrawal Work abeta accumulation aged alzhemed amyloid peptide amyloidogenesis base beta-site APP cleaving enzyme 1 brain tissue cognitive function design drug development experience extracellular familial Alzheimer disease flexibility fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether follow-up glycosylation homotaurine immunoregulation indexing intraneuronal beta amyloid lateral ventricle mimetics monomer mouse model novel novel strategies overexpression peripheral blood promoter radiotracer receptor binding research study response small molecule symposium theories therapeutic development therapy development time interval tool treatment duration vaccine efficacy

项目摘要

DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a neurodegenerative affliction associated with memory dysfunction. Pathological mutations in familial AD patients have been identified in several genes, and transgenic mice carrying pathological genes have been generated. The generation of transgenic models of amyloidosis has significantly aided progress in the development of therapeutic approaches designed to lower brain amyloid beta (Abeta) load. One of these approaches is called "immunization". Immunologically provoked (or passively administered) antibodies against Abeta have been shown to enhance microglial phagocytosis and reduce Abeta load in the brains of transgenic mice. Significantly, immunization also reversed Abeta associated memory dysfunction. Concomitant with reduced CNS Abeta is the simultaneous observation by us and others that plasma Abeta levels are significantly elevated following immunization. As a result of this observation, we have devised a new methodology to alter brain Abeta load, which has proved to be effective in preliminary studies. In the human active immunization clinical trial, Abeta vaccine approach was terminated after severe brain inflammation was found approximately in 6% of patients. The cause of brain inflammatory side effects is not clear yet, but it is most likely due to immune modulation. Although the first clinical trial of vaccine therapy was terminated, follow up reports are encouraging. Sequestration approach does not modulate immune reaction; therefore, it therapy has higher flexibility in drug development, and drugs based on sequestration approaches have less side effects. In addition, plasma Abeta elevation is a possible biomarker when this approach translates to clinical use. In this study, we will investigate the mechanism of Abeta sequestration mechanism and identify optimal molecular property and drugable target for future development of pharmacological therapy.

描述（由申请人提供）：阿尔茨海默病（AD）是一种与记忆功能障碍相关的神经退行性疾病。已鉴定出家族性AD患者的多个基因存在病理突变，并产生了携带病理基因的转基因小鼠。淀粉样变性转基因模型的产生极大地促进了旨在降低大脑β淀粉样蛋白（Abeta）负荷的治疗方法的开发进展。这些方法之一称为“免疫”。免疫激发（或被动施用）的 Abeta 抗体已被证明可以增强小胶质细胞的吞噬作用并减少转基因小鼠大脑中的 Abeta 负荷。值得注意的是，免疫还逆转了 Abeta 相关的记忆功能障碍。伴随中枢神经系统 Abeta 降低，我们和其他人同时观察到，免疫后血浆 Abeta 水平显着升高。根据这一观察结果，我们设计了一种改变大脑 Abeta 负荷的新方法，该方法在初步研究中已被证明是有效的。在人类主动免疫临床试验中，大约6%的患者发现严重脑部炎症后，Abeta疫苗方法被终止。大脑炎症副作用的原因尚不清楚，但很可能是由于免疫调节所致。尽管疫苗治疗的首次临床试验被终止，但后续报告令人鼓舞。隔离方法不调节免疫反应；因此，IT疗法在药物开发方面具有更高的灵活性，并且基于隔离方法的药物副作用较小。此外，当这种方法转化为临床应用时，血浆 Abeta 升高是一个可能的生物标志物。在本研究中，我们将研究 Abeta 隔离机制，并为未来药物治疗的发展确定最佳分子特性和药物靶点。